NCT02947867View on ClinicalTrials.gov

Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG

PHASE2/PHASE3UnknownINTERVENTIONAL

Enrollment

333

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

June 30, 2019

Study Completion Date

December 31, 2019

Conditions

Ischaemic Central Retinal Vein OcclusionNeovascular Glaucoma

Interventions

DRUG

aganirsen

aganirsen antisense oligonucleotide against Insulin Receptor Substrate (IRS-1)

Sponsors

Lead Sponsor

Gene Signal SAS

All Listed Sponsors

collaborator

Johannes Gutenberg University Mainz

OTHER

collaborator

University Hospital of Cologne

OTHER

collaborator

Moorfields Eye Hospital NHS Foundation Trust

OTHER

lead

Gene Signal SAS

INDUSTRY

NCT02947867 - Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG | Biotech Hunter | Biotech Hunter